Lake Street initiated Esperion with a Buy rating and $94 price taret. Analyst Carl Byrnes believes Experion has one of the most favorable risk/reward scenarios he has come across. Byrnes said The recent sell-off in shares has created a very compelling entry point for a company with a lead drug, ETC-1002, that has the potential to be a blockbuster addressing multi-billion dollar target markets.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here